Atyr Pharma Inc Dossier
Qualitative Analysis
Business overview
aTyr Pharma, Inc. (Nasdaq: ATYR) is a clinical-stage biotechnology company pioneering the discovery and development of first-in-class medicines derived from its proprietary tRNA synthetase platform. The company's research focuses on translating tRNA synthetase biology into novel therapeutics targeting fibrosis and inflammation. Its lead therapeutic candidate is efzofitimod, a selective modulator of Neuropilin-2 (NRP2) designed to downregulate inflammatory pathways without causing immune suppression. Efzofitimod is primarily being developed for interstitial lung diseases (ILDs), including pulmonary sarcoidosis and systemic sclerosis-related interstitial lung disease (SSc-ILD). Additionally, the company is advancing preclinical candidates such as ATYR0101 for fibrosis and ATYR0750 for liver disorders.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Following a Type C meeting with the FDA in mid-April 2026, aTyr is pivoting its clinical strategy for efzofitimod in pulmonary sarcoidosis. The company is launching a new global Phase 3 study specifically targeting chronic, symptomatic patients with restrictive lung disease, utilizing Forced Vital Capacity (FVC) as the primary endpoint and the King's Sarcoidosis Questionnaire (KSQ)-Lung score as a key secondary endpoint, with dosing administered intravenously every three weeks.
Expected impact: Establishes a validated regulatory pathway toward potential FDA approval by focusing on a high-unmet-need patient population with a primary endpoint (FVC) accepted by the FDA.
Advancing preclinical development of tRNA synthetase-derived candidates, specifically ATYR0101 (a fusion protein derived from aspartyl-tRNA synthetase targeting myofibroblast apoptosis and fibrosis reduction) and ATYR0750 (derived from alanyl-tRNA synthetase for liver disorders).
Expected impact: Expands the clinical-stage pipeline beyond the lead candidate efzofitimod, validating the therapeutic potential of the company's proprietary tRNA synthetase platform.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Kyorin held exclusive rights to develop and commercialize efzofitimod for interstitial lung diseases (ILD) in Japan. On May 12, 2026, aTyr announced the termination of this collaboration, which will take effect 90 days post-notice. As a result, global development and commercialization rights for efzofitimod revert entirely to aTyr.
Terms: The original agreement generated $20.0 million in upfront and milestone payments for aTyr. Due to the termination, aTyr forfeits eligibility for up to $155.0 million in remaining development, regulatory, and sales milestones, as well as future royalties on Japanese net sales.